Meloxicam Tablet
Product Images NDC 71610-544

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 71610-544). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 15 mg (71610 0544 30)

Meloxicam 15 mg oral tablets packaging label from Aphena Pharma Solutions - Tennessee, LLC. The label indicates a package of 30 tablets with storage instructions and a warning to keep out of reach of children. It includes the NDC number 71610-544-30 and mentions the manufacturer Ascent Pharmaceuticals, Inc.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Meloxicam Struct)

Chemical structure diagram of Meloxicam, showing the molecular arrangement including benzothiazine, sulfonamide, and thiazole rings with functional groups such as hydroxyl, carbonyl, and methyl groups.*

FDA Label Image

Tab1ab (Meloxicam Table 1)

A detailed table presenting adverse events occurring in 2% or more of Meloxicam patients in 12-week osteoarthritis and rheumatoid arthritis placebo-controlled trials. The table lists patient counts and percentages for various adverse event categories including gastrointestinal, nervous system, respiratory, skin, urinary, and body as a whole, comparing Meloxicam doses with placebo and other drugs like diclofenac and nabumetone.*

FDA Label Image

Tab2 (Meloxicam Table2)

A data table listing adverse reactions associated with Meloxicam tablets. The table categorizes side effects by body system including cardiovascular, central nervous system, gastrointestinal, hematologic, liver and biliary system, metabolic and nutritional, psychiatric, respiratory, skin and appendages, special senses, and urinary system.*

FDA Label Image

Tab3 (Meloxicam Table3)

This text panel details drug interactions of Meloxicam related to hemostasis, aspirin, ACE inhibitors, diuretics, lithium, methotrexate, cyclosporine, NSAIDs, salicylates, and pemetrexed. It outlines clinical impacts and intervention recommendations for each class when used concomitantly with Meloxicam.*

FDA Label Image

Table- 4 (Table 4)

Table 4 presents single dose and steady-state pharmacokinetic parameters for oral 7.5 mg and 15 mg meloxicam in healthy male adults, elderly males and females, as well as subjects with renal failure and hepatic insufficiency. Parameters include Cmax, tmax, half-life, clearance, and volume of distribution with mean values and percent coefficient of variation (% CV).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.